Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd.

Aged Antineoplastic Combined Chemotherapy Protocols / administration & dosage Disease-Free Survival Female Humans Male Middle Aged Multiple Myeloma / drug therapy Retrospective Studies Risk Factors Survival Rate
Bortezomib PI-triplet therapy RRMM carfilzomib ixazomib proteasome-inhibitor-triplet therapy real world relapsed refractory multiple myeloma

Journal

Expert review of hematology
ISSN: 1747-4094
Titre abrégé: Expert Rev Hematol
Pays: England
ID NLM: 101485942

Informations de publication

Date de publication:
04 2020
Historique:
pubmed: 10 3 2020
medline: 4 2 2021
entrez: 10 3 2020
Statut: ppublish

Résumé

Lack of head-to-head trials highlights a need for comparative real-world evidence of proteasome inhibitors plus Rd.

Identifiants

DOI: 10.1080/17474086.2020.1729734 PMID: 32148109
pubmed: 32148109
doi: 10.1080/17474086.2020.1729734
doi:

Types de publication

Comparative Study Journal Article Multicenter Study Research Support, Non-U.S. Gov't Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Pagination

421-433

Auteurs

Ajai Chari (A)

Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
ORCID: 0000-0002-0405-7480

Paul G Richardson (PG)

Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Dorothy Romanus (D)

Global Outcomes Research, Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.

Meletios A Dimopoulos (MA)

Hematology & Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
ORCID: 0000-0001-8990-3254

Pieter Sonneveld (P)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
ORCID: 0000-0002-0808-2237

Evangelos Terpos (E)

Hematology & Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
ORCID: 0000-0001-5133-1422

Roman Hajek (R)

University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.

Aditya Raju (A)

Scientific Consulting, Xcenda, Palm Harbor, FL, USA.

Antonio Palumbo (A)

Global Outcomes Research, Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.

Lauren E Cain (LE)

Global Outcomes Research, Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.

Marlo Blazer (M)

Scientific Consulting, Xcenda, Palm Harbor, FL, USA.

Hui Huang (H)

Global Outcomes Research, Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.

Eileen Farrelly (E)

Scientific Consulting, Xcenda, Palm Harbor, FL, USA.

Sikander Ailawadhi (S)

Division of Hematology/Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Real-world outcomes and factors impacting...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Real-world outcomes and factors impacting...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Survie sans rechute › Real-world outcomes and factors impacting...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Real-world outcomes and factors impacting...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Real-world outcomes and factors impacting...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Paraprotéinémies › Myélome multiple › Real-world outcomes and factors impacting...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Real-world outcomes and factors impacting...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › Real-world outcomes and factors impacting...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Mortalité › Taux de survie › Real-world outcomes and factors impacting...